Jeremy Chadwick Sells 300 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Key Points

• Jeremy Chadwick sold 300 shares of Kymera Therapeutics on April 22 at an average price of $90.00 for $27,000, leaving the COO with 61,202 shares (a 0.49% reduction) as disclosed in an SEC filing.
• Kymera stock traded down to $84.91 (down $2.26) with a market cap of about $6.93 billion; the company reported EPS of -$0.97 last quarter (missing estimates) and revenue of $2.87 million, down 60.8% year-over-year.
• Analysts remain generally positive, with several firms raising price targets (e.g., Piper Sandler to $140 and Barclays to $133) and a consensus rating of "Moderate Buy" and an average price target of $118.90.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) COO Jeremy Chadwick sold 300 shares of the stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $90.00, for a total value of $27,000.00. Following the transaction, the chief operating officer directly owned 61,202 shares of the company's stock, valued at approximately $5,508,180. The trade was a 0.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Kymera Therapeutics Stock Down 2.6%

Kymera Therapeutics stock traded down $2.26 during midday trading on Friday, reaching $84.91. 393,678 shares of the stock traded hands, compared to its average volume of 710,755. The stock's fifty day moving average is $84.58 and its 200-day moving average is $75.31. Kymera Therapeutics, Inc. has a 12 month low of $28.06 and a 12 month high of $103.00. The stock has a market cap of $6.93 billion, a P/E ratio of -23.07 and a beta of 2.28.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The firm had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. During the same period in the previous year, the company posted ($0.88) earnings per share. Kymera Therapeutics's quarterly revenue was down 60.8% on a year-over-year basis. On average, equities analysts predict that Kymera Therapeutics, Inc. will post -3.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Kymera Therapeutics

A number of large investors have recently bought and sold shares of the business. Baker BROS. Advisors LP boosted its holdings in Kymera Therapeutics by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company's stock valued at $673,620,000 after acquiring an additional 2,005,813 shares during the period. Avoro Capital Advisors LLC boosted its holdings in Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company's stock valued at $581,610,000 after acquiring an additional 1,124,747 shares during the period. Vanguard Group Inc. boosted its holdings in Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company's stock valued at $487,685,000 after acquiring an additional 845,922 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company's stock valued at $479,258,000 after acquiring an additional 1,061,957 shares during the period. Finally, State Street Corp boosted its holdings in Kymera Therapeutics by 9.4% during the 4th quarter. State Street Corp now owns 2,209,837 shares of the company's stock valued at $171,947,000 after acquiring an additional 190,383 shares during the period.

Analyst Upgrades and Downgrades

KYMR has been the subject of a number of research reports. Piper Sandler increased their price target on Kymera Therapeutics from $125.00 to $140.00 and gave the company an "overweight" rating in a research note on Thursday, February 26th. Barclays upped their price objective on Kymera Therapeutics to $133.00 and gave the company an "overweight" rating in a research report on Tuesday, January 27th. Jefferies Financial Group initiated coverage on Kymera Therapeutics in a report on Monday, March 16th. They issued a "buy" rating and a $110.00 target price for the company. Royal Bank Of Canada reiterated an "outperform" rating and issued a $108.00 target price on shares of Kymera Therapeutics in a report on Thursday, February 26th. Finally, Stephens lifted their target price on Kymera Therapeutics from $95.00 to $100.00 and gave the stock an "overweight" rating in a report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $118.90.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.